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Abstract
Introduction: The International Association for the Study of Pain has established a global task force to comprehensively investigate
the use of cannabinoids and cannabis-based medicines for pain management. This systematic review, the first in this field, will
assess the preclinical literature that investigates the antinociceptive effects of cannabinoids, cannabis-based medicines, and
endocannabinoid system modulators in animal models of tissue damage, inflammation, or neuropathy.
Methods:A systematic electronic search of 3 online databases will identify relevant studies in which cannabinoids, cannabis-based
medicines, and endocannabinoid systemmodulators have been tested in animal models of injury-related or pathological persistent
pain. Data will be extracted for pain-associated behavioural outcomes, study design, and the reporting of measures to avoid bias.
Standardised mean difference meta-analysis will be used to provide summary estimates of efficacy, with the effects of study quality
and study design explored using stratified meta-analysis.
Perspective: The evaluation of the preclinical evidence will quantify the antinociceptive effects of cannabinoids on pain behaviour in
animal models of pathological pain in an effort to quantify the presence and prevalence of analgesic efficacy. It will also provide an
understanding of the strengths and weaknesses of the preclinical field and inform an agenda for future research.
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1. Introduction
In 2018, the International Association for Study of Pain (IASP)
established a task force on the use of cannabis and cannabinoid-
based medicines (CBMs) for pain management. It comprised 4
work packages (WP) focused on (1) basic science, including
medicinal chemistry, compound classification, pharmacology,
and assessment of efficacy in preclinical studies; (2) evidence
synthesis on clinical efficacy and, where possible, effectiveness;
(3) evidence synthesis on harms; and (4) the societal impact
including changing policy and political practice. This review will
inform WP1 and is focused on summarising the preclinical
evidence for the efficacy of cannabinoids and CBMs in animal
models of pathological or injury-related persistent pain. WP2 will
focus on summarising the evidence for both efficacy and harms
as measured within randomised controlled trials of cannabinoids
and CBMs in addition to providing a review of all previous
systematic reviews (PROSPERO IDs CRD42019124714 and
CRD420191247). Harms data from randomised controlled trials
will be addressed in a third concurrent review (WP3) (PROSPERO
IDXXXXXXXXXX [to be inputted when registered]).
For thousands of years, the plant Cannabis sativa has been
used to treat various medical conditions including nausea,
convulsions, and pain. The endocannabinoid system—consist-
ing of the cannabinoid 1 receptor (CB1) and cannabinoid 2
receptor (CB2), endogenous cannabinoid ligands (endocannabi-
noids), and their metabolising enzymes—is implicated in pain
signalling pathways. Cannabinoids are a diverse class of
biologically active constituents of cannabis or synthetic com-
pounds, which usually have affinity for and activity at cannabinoid
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receptors. The most studied plant-derived cannabinoids (phyto-
cannabinoids) are D9-tetrahydrocannabinol, the main psychoac-
tive constituent in cannabis, attributable to its binding to CB1
receptors, and cannabidiol, which does not bind to cannabinoid
receptors (reviewed by Fine and Rosenfeld9); Table 1 provides
current terminology, definitions, and examples of typical prod-
ucts. The endocannabinoid system has been studied extensively
in animal models, and endocannabinoids, phytocannabinoids,
and synthetic cannabinoid receptor agonists have been reported
to have antinociceptive effects in animal models of acute,
inflammatory, and neuropathic pain (for review see Refs. 11,
15, and 18). Very recently, a mutation in the endocannabinoid
signalling pathway has been found to be associated with
congenital insensitivity to pain.7
With increasing scrutiny of the field and mounting global
pressure for the legalisation of medicinal cannabis, it is crucial
to assess the existing evidence in an unbiased and robust
manner including that from preclinical studies. Pain cannot be
measured directly in nonhuman animals. Animal models of
disease states or toxic challenges known to induce pain in
humans have been developed. These models are used to
investigate the pathophysiology underlying chronic pain and
have enriched our understanding. They have been used to test
the efficacy of novel therapeutics and therefore provide
justification for clinical trials. The number of preclinical experi-
ments performed each year is rising exponentially but the
number of novel interventions reaching the clinic continues to
fall. Failure to translate to patients success observed in
preclinical studies has led to the questioning of the predictive
validity of animal models. There are many reasons for the
disparity between animal model and clinical trial results
including the complexity of human trials. Lack of scientific
rigour and/or transparent reporting across many preclinical
fields of biological research may contribute to the lack of
translation in addition to methodological differences across
studies.1 The extent to which there is conclusive evidence for
efficacy of cannabinoids for chronic pain in humans is still
somewhat controversial, with different systematic reviews
coming to differing conclusions. This aspect is being
addressed by the 2 other IASP Cannabinoid Taskforce
protocols for systematic reviews of the corresponding clinical
literature. Therefore, there is a strong rationale for better
understanding the preclinical efficacy data on cannabinoids in
animal models of pathological or injury-related persistent pain,
to better inform future translational and clinical research. A
systematic review conducted in accordance with the guidance
as stipulated by Sena et al.13 will provide an unbiased
framework to appraise the relevant preclinical literature. It will
produce empirical evidence to achieve a dual goal of de-
termining the efficacy of specific cannabinoids and cannabis-
based medicines in pain models, and to inform future
experimental and clinical trial design.
This review also aims to use a crowd. Preclinical systematic
reviews are still novel, but they are vital research tools, important
for evidence-based research planning and decision making. In
addition, systematic reviews are an effective approach to
consolidating the high-volume, rapidly accruing, and often
conflicting research on a specific topic. The methods for their
conduct are well developed, but they are resource intensive.16
The most labour-intensive stages are screening, annotation, and
outcome data extraction, which requires a minimum of 2
reviewers and a third independent reviewer to reconcile any
disagreements thereby minimising the risk of bias and ensuring
reliability. The time they take to complete weakens their
Table 1
Terminology and definitions (modified from Hauser et al.9).
Term Definition Examples/typical products
(Herbal) cannabis The whole plant or parts or material from the plant
(eg, flowers, buds, resin, and leaves)
Cannabis sativa, hashish
Medical cannabis The term “medical cannabis” (or “medical
marijuana”) is used for cannabis plants, plant
material, or full plant extracts used for medical
purposes
Bedrocan, Bedrobinol, Tilray 10THC/10CBD
Cannabinoids Cannabinoids are biologically active constituents of
cannabis, or synthetic compounds, usually having
affinity for and activity at cannabinoid receptors
THC, CBD, CP55,940, WIN55,212‐2, HU210,
nabilone, AM1241, AM1710, JWH133,
LY2828360. MDA19
Phytocannabinoid A cannabinoid found in the cannabis plant or
purified/extracted from plant material
THC, CBD, CBDA
Endocannabinoid An endogenous ligand found in the body of humans
and other animals and which has affinity for, and
activity at, cannabinoid receptors
Anandamide, 2-AG
Endocannabinoid system modulators In addition to individual phytocannabinoids,
cannabis-derived or cannabis-based medicines,
and cannabis extracts, other pharmacological
approaches under development for manipulation of
the endocannabinoid system include selective
synthetic cannabinoid receptor agonists or
antagonists, inhibitors of the catabolism (eg, fatty
acid amide hydrolase [FAAH] inhibitors), transport
(eg, fatty acid binding protein [FABP] inhibitors), or
reuptake of endocannabinoids or allosteric
modulators of cannabinoid receptor signalling
PF-04457845, URB597, URB937, AM404,
VDM11, URB602, JZL184, ZCZ011, GAT211,




Registered medicinal cannabis extracts with
defined and standardized phytocannabinoid
content, particularly THC and THC/CBD
Nabiximols (Sativex), dronabinol, marinol, Epidiolex
2‐AG, 2‐arachidonoyl glycerol; CBD, cannabidiol; FABP, fatty acid binding protein; THC, tetrahydrocannabinol.
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usefulness because they are often out of date once they have
been published.14 This problem is being exacerbated by the
exponentially increasing number of publications in databases.2
A growing amount of research is conducted in an open
collaborative fashion, in projects referred to as “crowd science,”
“citizen science,” or “networked science.” Challenging tradi-
tional ways of working using a crowd offers a novel opportunity
to improve the efficiency and accuracy of a review.9 By breaking
down the review process into microtasks, systematic reviews
can be conducted more efficiently by a wider range of people
and the crowd will be used to conduct tasks that require
common scientific skills.
1.1. Aims and objectives
The aims of this systematic review and meta-analysis are to (1)
estimate the antinociceptive efficacy of cannabinoids in animal
models of pathological or injury-related persistent pain (ie,
typically studied over a period of hours, days, weeks, or months,
not acute nociception), (2) assess the impact of the studies’
internal and external validity on reported behavioural outcome
measures, and (3) to identify the presence of publication bias and
determine its magnitude.
2. Methods
2.1. Crowd recruitment and training
Ethical approval to use a crowd has been obtained from
Imperial College London’s Head of Surgery and Cancer and
Science, Engineering and Technology Research Ethics
Committee.
The recruitment strategy aims to predominantly target
bioscientists who are interested in contributing to an
important area of research and looking for professional
development opportunities. As such, participants will have
widely varied experience of the topic and the systematic
review process. An advertisement has been developed with
IASP, which will be shared widely through the IASP network,
collaborators, colleagues, and students using direct commu-
nication, e-mail, newsletters, social media, and face–face
interactions at conferences and workshops. Participants will
be asked to e-mail in response to the advertisement and will
then receive a registration form, participant information sheet,
and consent form and once these enrolment activities are
complete, the participant will be invited to commence the
training. There is not a required minimum/maximum number
of participants to meet the needs of the review. Reviewers do
not need to meet a requisite criteria but will be required to
successfully complete the training to participate.
Participants will receive training using an online platform (Learn
to SyRF), which will be supported by a training manual with
comprehensive instructions. They will need to conduct training for
both screening and data extraction. To pass the screening training,
participants will need to correctly make the include or exclude
decisions for 10 consecutive publications. For data extraction, they
will be presented with studies to extract data from, and their data
extraction will be compared with a “gold standard” derived
following review of a set of studies conducted in house by the
team. Once their concordance with that gold standard is greater
than 80% for 3 successive studies, they will be considered to have
been trained to a sufficient standard. Participants will not be able to
contribute to the systematic review if they fail to complete the
training or do not meet the required standard.
2.2. Protocol registration
The protocol for this systematic review is registered on
PROSPERO (PROSPERO ID CRD4201912804). The protocol
uses the template designed by the Systematic Review Centre for
Laboratory Animal Experimentation.4
2.3. Study population
Whole in vivo animal models of pathological or injury-related
persistent pain (eg, tissue injury, cancer, chemotherapy-induced,
toxic neuropathy, inflammation, or nerve damage) that receive
any cannabinoid-related therapeutic, including endocannabinoid
modulators, will be included. Studies of acute physiological
nociception will be excluded.
2.4. Control population
For studies that investigate cannabinoid treatment efficacy in
a model of injury-related or pathological persistent pain, the
control population is defined as a cohort of animals in which the
model has been induced but there has been an appropriate
control treatment (eg, injection of vehicle or saline).
2.5. Outcome measures
Pain-associated behavioural measures as declared by the
authors will be extracted, ie, pain is declared the reason for the
assessment. Behavioural measures not associated with pain or
aimed to assess the potential unwanted side effects of
cannabinoids will be excluded. Behavioural outcomes are likely
to include (but not an exhaustive list)
(1) Evoked limb withdrawal (eg, von Frey withdrawal threshold,
Plantar test [Hargreaves’], and thermal footplate)
(2) Mechanical allodynia/hypersensitivity
(3) Cold allodynia/hypersensitivity (eg, acetone test)
(4) Heat hypersensitivity
(5) Spontaneous behavioural outcomes (eg, weight bearing
difference, spontaneous foot lifting, burrowing and grimace
scale; nocifensive behaviour)
(6) Motor tests (eg, rotarod, CatWalk)
(7) Complex behavioural outcomes (eg, elevated plus maze,
open field [thigmotaxis], and conditioned place preference or
aversion).
To inform a narrative review, included studies that contain the
following will be annotated (systematic identification of relevant
studies):
(1) Whether the study investigated the effects of drug on
non–pain-related motor activity.
(2) Electrophysiology (eg, wide dynamic range and nociceptive-
specific cells)
(3) Markers for neuronal activity (eg, c-Fos, ERK, p38 MAPK)
(4) Whether CB1/CB2 receptor has been confirmed as the target
(eg, antagonism, knockout control; inactive enantiomer
control, tolerance consistent with receptor mediation)
2.6. Systematic search
To identify all relevant studies PubMed, Embase, and Web of
Science databases will be searched. To ensure that the search
has the highest probability of identifying all applicable studies,
a broad search strategy will be used and optimised for each of the
databases. It will include all languages and dates, but publication
types will be limited to not include editorial materials, book
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chapters, biographical items, reviews, notes, letters, or news
items. The general search terms are given below; full search
strategy can be found on the Open Science Framework
Cannabinoid Preclinical SR search strategy:
Cannabinoids OR cannabis OR marijuana OR marihuana OR
hemp OR hashish OR cannabinoid OR cannabinoids OR
cannabidiol OR tetrahydrocannabinol OR “endocannabinoid
modulator” OR FAAH OR MGL OR MAGL OR ABHD6 OR
ABHD12 OR “fatty acid binding protein” OR NAAA OR
endocannabinoid OR endocannabinoids OR endo-cannabinoid
OR FAAH inhibitor OR FAAH inhibition OR MAGL inhibitor OR
MAGL inhibition OR MGL inhibitor OR MGL inhibition OR
anandamide transport inhibitor OR anandamide transport in-
hibition OR “ABHD6 inhibitor” OR “ABHD6 inhibition” OR
“ABHD12 inhibitor” OR “ABHD12 inhibition” OR NAAA inhibitor
OR NAAA inhibition OR “Fatty acid Binding Protein inhibitor” OR
“fatty acid binding protein inhibition” OR FABP inhibition OR
FABP inhibitor OR allosteric modulator OR “endocannabinoid
modulators” OR “endo-cannabinoid modulators” OR “endo-
cannabinoid modulator” OR FAAH inhibitors OR MAGL inhibitors
OR MGL inhibitors OR anandamide transport inhibitors OR
“ABHD6 inhibitors” OR “ABHD12 inhibitors” OR NAAA inhibitors
OR “Fatty acid Binding Protein inhibitors” OR FABP inhibitors OR
allosteric modulators OR PEA OR palmitoylethanolamide AND
Pain OR Hyperalgesia OR pain OR analgesia OR analgesic OR
analgesics OR allodynia OR neuralgia OR hypersensitivity OR
hyperalgesia OR hyperalgesic OR antinociception OR anti-
nociception OR hypoalgesia OR hypoalgesic OR anti-
hyperalgesia OR antihyperalgesia OR antihyperalgesic OR anti-
hyperalgesic OR anti-allodynic OR antiallodynic OR anti-allodynia
OR antiallodynia AND Animal search filters.5,8
2.7. Before screening
The search results will be imported to Endnote and duplicates
removed using the Endnote tool. The studies will then be
exported from Endnote in XML format into the CAMARDES
(Collaborative Approach to Meta-Analysis and Review of Animal
Data from Experimental Studies, University of Edinburgh)
Systematic Review Facility (SyRF; http://syrf.org.uk/), a fully
integrated online platform for preclinical systematic reviews.
2.8. Screening and study design criteria
The screening process requires a minimum of 2 independent
reviewers, but this review seeks to use a “crowd” as the second
reviewer. Any discrepancies will be resolved by a “third” in-
dependent reviewer.
Studies that investigate a cannabinoid administered to a whole
animal model of pathological or injury-related persistent pain in
which pain relevant behavioural outcomes are presented with an
appropriate control will be included. Multiple routes of drug
administration will be considered (eg, intraperitoneal, intrave-
nous, subcutaneous, intrathecal, intraplantar, intraventricular,
and intracranial [eg, periaqueductal gray, rostral ventromedial
medulla, and anterior cingulate cortex]). Publications or abstracts
without data, retrospective studies, review articles, in vitro
studies, case reports, human studies, letters, and comments will
be excluded.
Screening will be conducted based on title and abstract
(whole text if ambiguous). It is the aim to usemachine learning to
reduce the number of studies that need to be screened
manually. To achieve this, half of the studies will be screened
manually to establish a training set. This data set will then be
used to train a machine-learning algorithm10 to screen the
remainder. However, it may be that the training set does not
provide enough instances to train the machine, perhaps due to
the low volume of studies and complex categorisations;
therefore, it may be a requirement to continue screening
manually.
2.9. Animal inclusion criteria
(1) Animal models of pathological or injury-related persistent pain
(2) Transgenic studies for which pain is resultant, eg, diabetes.
(3) Male and female animals
(4) Primary focus will be adolescent and adult animals. Studies in
neonatal animals will also be captured if pathological or injury-
related persistent pain was induced.
(5) Multiple models presented as a single model, eg, HIV plus
antiretroviral drug
2.10. Intervention inclusion criteria
Any monotherapy and/or combination treatment given before/
after/in concurrence with the model induction.
2.11. Exclusion criteria
(1) Human studies
(2) Studies of acute physiological nociception
(3) In vitro and ex vivo studies
(4) Not an original research article containing cannabinoid
intervention to a pathological persistent pain animal model.
Publications or abstracts without data, retrospective studies,
review articles, case reports, letters, and comments.
3. Data extraction
Similarly, the data extraction process requires a minimum of 2
independent reviewers but this review seeks to use a “crowd” as
the second reviewer. Any discrepancies will be resolved by
a “third” independent reviewer.
3.1. Study bibliographic data
The title, first author, corresponding author, year, journal name,
and DOI of each study will be extracted.
3.2. Study design characteristics
The number of animals in the experimental and control groupswill
be extracted. If the number of animals is given as a range, the
most conservative estimate will be recorded. The number of
different behavioural assessments (therefore, outcome meas-
ures) a group of animals was tested on will also be extracted.
3.3. Animal model characteristics




(4) Animal age and/or weight
(5) Animal supplier
(6) The category of model
(7) The method used to induce the model (including dose if
pharmacologically induced)
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(8) The time between model induction and outcome
measurement
(9) Perioperative analgesia used during model induction
3.4. Intervention (treatment) characteristics
(1) Intervention type (and vehicle)
(2) Cannabinoid pharmacological classification
(3) Dosing regimen
(4) Time of first dose
(5) Route of administration
(6) Time between the administration of the treatment and
outcome measurement
(7) Time between the model induction and treatment
3.5. Collection of outcome data
Model behavioural outcomes measured must be compared to
a suitable control; a separate control group, the same animal cannot
beused for both, eg, contralateral is not a suitable control for ipsilateral
due to the possibility of contralateral sensory changes that could affect
outcome measures. For graphs or if numerical data are described in
tables/within the text comparing (pain model 1 treatment) vs (pain
model1 vehicle), the data at the time point at which the drug is most
effectivewill be extracted (ie, the timepoint atwhich there is the largest
difference between treatment and control) to allow for efficacy to be
estimated.
The mean and standard error or SD (studies which present the
data as medians will be annotated to give reviewers the option to
revisit these studies if deemed necessary) will be extractedmanually
using universal desktop ruler and/or the inbuilt Adobemeasuring tool
and/or WebPlotDigitizer (reviewers’ preference). It may be an option
to use bespoke PDF data extraction tools (https://github.com/EPPI-
Centre/Graph2Data) that are currently being integrated into the
SyRFplatform. The tools have been shown to improve accuracy and
reduce the time required for data extraction.3
3.6. Risk of bias and study quality
Study quality will be assessed against the reporting of the
following items that may represent risks to study validity:
(1) Random allocation of animals to treatment/control groups
(2) Blinded conduct of the experiment
(3) Blinded assessment of outcome
(4) Statement of sample size calculation
(5) Reporting of animal exclusions
In addition:
(1) Statement regarding possible conflicts of interest
(2) Statement of compliance with animal welfare regulations
Reviewers will select whether these criteria are reported. They
will then be required to state the method that the experimenters
used so that a risk-of-bias assessment can be conducted in
terms of high, low, or unclear risk of bias.
4. Data synthesis
The included studies will be organised according to the type of
disease/injury model being studied, e.g., inflammation- or
chemotherapy-induced neuropathy, followed by outcome measure
and then drug (classification, drug name, dose, and route of
administration) andwhether it was administered before or after model
induction (prophylactic or therapeutic intervention) and if in combina-
tion (eg, FAAH-COX, with an opioid, gabapentin, or antidepressant).
A meta-analysis will be conducted in accordance with the
guidelines described by Vesterinen et al.17 and aims to:
(1) Calculate an effect size for each comparison
(2) Weight the effect sizes
(3) Calculate a summary effect size
(4) Calculate the heterogeneity, and the extent to which the study
design characteristics explain this heterogeneity
4.1. Calculating effect size (standardised mean difference)
For each comparison—where outcome in a cohort of animals
receiving treatment is presented, along with that for a control
cohort—an effect size will be calculated (correction for multiple
uses of control group: where a single control group serves
multiple treatment groups, the size of the control group entered to
the meta-analysis will be adjusted by division by the number of
treatment groups served.). The Hedge’sGmethod will be used to
calculate the standardised mean difference. The difference in
group means will be divided by a measure of the pooled variance
to convert all outcome measures to a standardised scale with
units of SDs. This allows for data where different measurement
scales are reported for the same outcomemeasure. This method
also includes a correction factor for small sample biases. Small
samples are considered groups of less than 10 animals.12
4.2. Weighting effect sizes
Weights are attributed to each study to reflect the contribution of
individual studies to the total effect estimate and this is done
according to the precision of the study. The weights will be
calculated using the inverse variance method; individual effect
sizes are multiplied by the inverse of their squared standard error.
4.3. The statistical model of analysis
A random-effects model will be used. This considers both the
within-study (sampling error) and between-study (differences in
the true effect size) variance. The distribution of effect sizes has
a weighted mean (the summary estimate), a weighted sum of the
square of the deviations from that mean (the heterogeneity), and
an estimate of the variance of the effect sizes beyond that
expected by chance (tau-squared, t2). From the standard error,
the 95% confidence intervals can then be calculated.
4.4. Assessing heterogeneity
I2 will be used to estimate the between-study heterogeneity. It is
defined as the proportion of total variance between studies that is
due to true differences in effect sizes as opposed to chance. I2 lies
between 0% (all variation due to chance) and 100% (all variation
reflects real differences between the effect sizes between studies
and does not depend on the number of comparisons in themeta-
analysis). 0%–25% reflects low heterogeneity, 50%–75% mod-
erate heterogeneity, and .75% high heterogeneity.
4.5. Examining sources of heterogeneity
Stratified meta-analysis will be performed according to study
quality; components of study quality checklist; type of outcome
measure; species, strain, sex, and age of animal used; outcome
measure used; and interval to quantification of outcome. Rats
and mice will be analysed separately. The heterogeneity between
groups will be tested using the x2 distribution.
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4.6. Assessing publication bias
(1) Funnel plots will allow for visual identification of studies with
small precision that overstate the effect size and are consistent
with the presence of small study publication bias
(2) Trim and fill analysis nonparametrically will attempt to correct
for funnel plot asymmetry by identifying and imputing
theoretically missing studies. This enables a recalculation of
the overall effect size in the absence of publication bias
(3) Egger’s regression will allow for statistical assessment of the
presence of publication bias from the funnel plot. It determines
whether the regression line and its 95%confidence interval, for
precision vs standardised effect size intersect at the origin of
the graph.
5. Discussion
This systematic review and meta-analysis will form part of wider
body of work instituted by the International Association for the
Study of Pain. It will provide an overview of the available
evidence in the field of cannabinoid preclinical research. It will
allow for the quantification of the analgesic or antinociceptive
effect of cannabinoids and CBMs in animals models of
pathological or injury-related persistent pain as well as providing
an appreciation of the rigour of the data. The empirical evidence
gained will allow for practical recommendations for the
improvement of future research; it will be used to identify
knowledge gaps, factors influencing treatment efficacy, inform
experimental design of new studies, and reduce waste in future
research.
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